Rodman & Renshaw started coverage on shares of Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) in a report issued on Tuesday, Marketbeat Ratings reports. The firm set a "buy" rating and a $7.00 price target on the stock. Rodman & Renshaw's price objective would suggest a potential upside of 432.32% from the stock's previous close.
Separately, HC Wainwright restated a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research note on Wednesday, December 18th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Cardiol Therapeutics presently has an average rating of "Buy" and an average price target of $8.40.
View Our Latest Analysis on CRDL
Cardiol Therapeutics Price Performance
Shares of CRDL stock traded up $0.03 during mid-day trading on Tuesday, reaching $1.32. The company's stock had a trading volume of 172,623 shares, compared to its average volume of 264,373. Cardiol Therapeutics has a 1-year low of $0.96 and a 1-year high of $3.12. The company has a market cap of $108.63 million, a P/E ratio of -3.37 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49. The firm's 50-day moving average is $1.39 and its two-hundred day moving average is $1.80.
Institutional Investors Weigh In On Cardiol Therapeutics
Several large investors have recently made changes to their positions in the company. Lion Street Advisors LLC grew its holdings in shares of Cardiol Therapeutics by 12.6% in the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company's stock worth $396,000 after purchasing an additional 34,385 shares during the last quarter. Foundations Investment Advisors LLC grew its holdings in Cardiol Therapeutics by 237.4% during the 3rd quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company's stock worth $321,000 after acquiring an additional 113,950 shares during the last quarter. Jane Street Group LLC bought a new stake in Cardiol Therapeutics during the 3rd quarter worth about $29,000. Townsquare Capital LLC bought a new stake in Cardiol Therapeutics during the 3rd quarter worth about $27,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Cardiol Therapeutics during the 3rd quarter worth about $27,000. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
